Person: AKASLAN, TAHSİN ÇAĞDAŞ
Importance of Follow Up in Determining PSA Prevalence of PSA in Turkish Psoriasis Patients
2019-06-15T00:00:00Z, GÜNEŞ, BEGÜM, GÜLCAN, ALİYE SEVDEM, DİZMAN, DİDEM, BAHALI, ANIL GÜLSEL, AKASLAN, TAHSİN ÇAĞDAŞ, REZVANİ, AYLİN, ONSUN, NAHİDE, GÜNEŞ, BEGÜM, GÜLCAN, ALİYE SEVDEM, BAHALI, ANIL GÜLSEL, AKASLAN, TAHSİN ÇAĞDAŞ
Scabies increase during the COVID-19 pandemic: should we change our treatment strategy during the pandemic?
2022-01-01T00:00:00Z, MERT, ÖMER, SU KÜÇÜK, ÖZLEM, AKASLAN, TAHSİN ÇAĞDAŞ, MERT, ÖMER, SU KÜÇÜK, ÖZLEM
Scabies is a highly contagious, parasitic infestation caused by Sarcoptes scabiei var. hominis. There are some reports which claim the incidence of scabies has increased during COVID-19 lockdown. In this study, we aimed to compare the prevalence of scabies between March to September 2020 - the first six months of the COVID-19 outbreak in Turkey - and March to September 2019 - the same period in the previous year. Case number percentages were compared month-over-month and by total numbers for each specified period. Pearson-s chi-squared test was the comparison tool used. We checked the records of 36,469 patients who were admitted to Bezmialem Vakif University, Faculty of Medicine, Dermatology Department, a tertiary healthcare center, between March and September 2019, and out of this number, 258 patients had been diagnosed with scabies. The overall scabies case percentage was 0.71% and the range of monthly prevalence was 0.57%-0.83%. During the corresponding period in 2020, 26,219 dermatology patients were admitted, and 465 of those patients were diagnosed with scabies. The overall scabies case percentage was 1.77% and the range of monthly prevalence was 1.37%-3.46%. Scabies prevalence percentages were statistically significantly higher in all months and in the overall total in 2020 (P<0.001). Our nine patients, who admitted in 2020, did not respond to permethrin treatment but responded well to an ivermectin and permethrin combination. Scabies incidence has increased during the COVID-19 pandemic according to our study. We believe there may be an underreported resistance to permethrin and that starting treatment with oral ivermectin in combination with topical permethrin in extraordinary times, such as a pandemic, may help to control outbreaks.
Clinical and histopathological improvement of scleromyxedema-induced microstomia after hyaluronidase injection
2022-05-01T00:00:00Z, AKASLAN, TAHSİN ÇAĞDAŞ, YILDIZ, PELİN, ONSUN, Nahide, AKASLAN, TAHSİN ÇAĞDAŞ, YILDIZ, PELİN, ONSUN, NAHIDE
Introduction Scleromyxedema is a rare primary cutaneous mucinosis characterized by numerous firm, waxy, confluent papules. Recently, intravenous immunoglobulin (IVIG) is accepted by many authors as the first-line treatment option for severe cases. We report a 69-year-old male patient who has been suffering from scleromyxedema, with reduced mouth opening. He has been on a high-dose IVIG regime for 5 years. Methods The patient stated that he had difficulty in wearing and removing his dentures because of reduced mouth opening lately. Before considering to add any other immunosuppressants to his regime, we injected 1500 IU of hyaluronidase in total in one session periorally. The patient has been told open his mouth maximum and photographs have been taken before injections and after one month. We used a photo measurement application when evaluating microstomia to increase accuracy. We also took punch biopsies in order to evaluate effect of hyaluronidase histopathologically before and one month after injections. Results One month later, he was able to reattach and remove his dentures without adding any adjuvant immunosuppressants other than hyaluronidase. Mouth opening was increased in measurements and histopathologically, mucin deposition, fibroblastic proliferation, and perivascular lymphocytic infiltration were decreased. Conclusions We think hyaluronidase is a safe, easily accessible, and effective treatment option for microstomia caused by scleromyxedema.
Importance of follow -up in determining PsA and prevelance of PsA in Turkish psoriasis patients
2019-06-07T00:00:00Z, Onsun, Nahide, Yurtsever, Begüm, Gülcan, Aliye Sevdem, Dizman, Didem, Akaslan, Tahsin Çağdaş, Bahalı, Anıl Gülsel, ONSUN, NAHIDE, GÜLCAN, ALİYE SEVDEM, DİZMAN, DİDEM, AKASLAN, TAHSİN ÇAĞDAŞ, BAHALI, ANIL GÜLSEL
Introduction: Psoriasis is classified as an immune-mediated inflammatory disease (IMID) ofthe skin and associated with comorbidities. Between 6-42% of patients with psoriasisdevelop psoriatic artrihitis (PsA) and nearly all patients with PsA have cutenous psoriasis.PsA usually develops after psoriasis and dermatologists can detect early signs of arthritis onfollow-up visits.Objective: We aimed to point out the importance of follow up of patients with cutaneouspsoriasis in detecting earlier symptoms of arthritis.Patients and Methods: We reviewed the records of patients with psoriasis from the psoriasisregistry of Turkey (PSR-TR). Records of the patients between 2006-2018 were reviewed.Patients with arthritis were divided into two groups; patients with arthritis in the firstexamination and patients who were diagnosed on subsequent visits.Results: Of the total 2880 patients, 713 of them had arhtiritis. The number of patientsdiagnosed in the first examination was 409 (58%) and the number of patients who werediagnosed during follow-up was 304 (42%).Conclusions: Psoriatic arthritis is closely associated with psoriasis and can lead tosignificant morbidity. Dermatologists are able to screen patients for early psoriatic arthritis.Regular follow up of patients and screening for arthritis who had no sign in the firstexamination, will point out the real prevelance of arthritis in psoriasis.